SkinVision vs MiiSkin: AI Analysis vs Mole Tracking Compared
SkinVision and MiiSkin are two of the best-known mole apps, and they are often compared - but they are built for different jobs. SkinVision uses AI to analyse a photo and rate a spot's risk. MiiSkin is designed to track moles over time by comparing photos. This guide compares them fairly on what they do, cost, and privacy - and covers a free web-based option if you would rather not subscribe or upload images.
SkinVision: AI risk assessment
SkinVision is CE-marked as a medical device in Europe and uses machine learning to classify a photographed spot as low, medium, or high risk. Pricing is a subscription, around $50/year for unlimited checks.
Strengths: an instant AI risk read, a large training dataset, and medical-device certification. Weaknesses shared by all photo AI: accuracy varies with photo quality and lighting, and performance is weaker on darker skin tones.
MiiSkin: change detection over time
MiiSkin focuses on tracking rather than instant AI verdicts. It helps you photograph moles consistently and compare them side by side to catch change - the key melanoma signal. It has a free tier and premium features by subscription.
Strengths: strong photo-comparison and monitoring tools. Weaknesses: limited AI analysis, and premium features sit behind a paywall.
Head to head: cost, privacy, and what they answer
What they answer: SkinVision answers 'does this spot look risky now?'; MiiSkin answers 'has this spot changed over time?' Cost: both use subscriptions, though MiiSkin has a usable free tier. Privacy: both are photo-based, so both store images of your skin - unavoidable for AI analysis and for photo tracking respectively.
If you want a single instant verdict, SkinVision fits. If you want disciplined long-term monitoring, MiiSkin fits. Many users would genuinely benefit from both jobs, which is why neither fully replaces the other.
The free alternative: criteria-based web screening
If you are comparing these two mainly to avoid a dermatologist bill, there is a third option for the screening question. A free web tool like CheckMole's ABCDE checker walks you through the same clinical criteria with no download, no subscription, and no photo upload.
It will not give you AI photo analysis or automated tracking, but for the common 'should I worry about this specific spot' question it is instant and free - and it pairs well with a simple photo diary for tracking.
The bottom line
There is no single winner - it depends on the job. Pick SkinVision for AI risk reads, MiiSkin for tracking change, and a free web checker if you want an instant, no-cost, no-upload screen. All three are triage tools, not diagnoses.
Whichever you choose, the rule that outranks every app: a mole that is changing, bleeding, itching, or not healing - or that looks different from your others - needs a dermatologist, because only a biopsy can diagnose skin cancer.
Don't want to pay or upload a photo just to check one spot? Run it through our free ABCDE checker for an instant read - then see a dermatologist for anything suspicious or changing.
Start free ABCDE checkFrequently asked questions
Should I use SkinVision or MiiSkin?
SkinVision gives an instant AI risk read from a photo; MiiSkin tracks whether a spot changes over time. Pick based on which question you are actually asking.
Is there a free alternative to SkinVision and MiiSkin?
Yes - a criteria-based web tool like CheckMole's ABCDE checker screens a spot for free with no photo upload or subscription.
Do SkinVision and MiiSkin both require photo uploads?
Yes, both are photo-based - SkinVision for AI analysis, MiiSkin for side-by-side comparison over time.
Which app is cheaper, SkinVision or MiiSkin?
MiiSkin has a usable free tier; SkinVision is subscription-only at around $50/year. Both have premium tiers for their full feature sets.
Sources
Content based on clinical guidelines from the American Academy of Dermatology (AAD), British Association of Dermatologists (BAD), and peer-reviewed literature from JAAD, BJD, and JAMA Dermatology. Epidemiological data from NCI SEER and IARC GLOBOCAN. Full methodology